LONDON, Ontario & BOSTON--(BUSINESS WIRE)--Viron Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the commercialization of novel anti-inflammatory therapeutics, today announced that Claude R. Benedict, M.D. has been appointed the Company’s Senior Vice President, Clinical Development and Regulatory Affairs. Dr. Benedict brings over thirty years of medical and pharmaceutical experience to Viron, including leadership positions at Archemix Corporation and Aventis Pharmaceuticals.
